SCHEMBL24170474

SCHEMBL24170474

CC(C)NC(=O)C(C)(C)CC(C)(C)C1CCCCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.44
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
MMP2 P08253 2/20 0.36
CA9 Q16790 2/20 0.36
EPHX1 P07099 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
ALOX12 P18054 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SSTR4 P31391 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
CCR2 P41597 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25617121 0.83 SMN1; SMN2 (0.36) SIGMAR1EPHX1SMN1; SMN2MEN1KMT2A
SCHEMBL24458985 0.78 SIGMAR1 (0.37) SIGMAR1CA12CA1CA2MMP2
SCHEMBL21362938 0.77 SMN1; SMN2 (0.36) EPHX1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL13997881 0.77 SMN1; SMN2 (0.39) EPHX1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL13997926 0.77 SMN1; SMN2 (0.39) EPHX1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL10170223 0.74 SIGMAR1 (0.35) SIGMAR1CA12CA1CA2MMP2
SCHEMBL9359725 0.72 SMN1; SMN2 (0.33) EPHX1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2994447 0.71 MEN1 (0.40) EPHX1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL20625818 0.71 MMP8 (0.37) SIGMAR1CA12CA1CA2MMP2
SCHEMBL18827271 0.71 SIGMAR1 (0.33) SIGMAR1CA12CA1CA2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022000443-A1 METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS Nanjing Immunophage Biotech Co., Ltd. (CN) 2022-01-06 WO disclosed